Annual report pursuant to Section 13 and 15(d)

Commitments and Contingencies (Details Textual)

Commitments and Contingencies (Details Textual) (USD $)	12 Months Ended		0 Months Ended	1 Months Ended	0 Months Ended	1 Months Ended			12 Months Ended	0 Months Ended	1 Months Ended
Commitments and Contingencies (Details Textual) (USD $)	Dec. 31, 2014	Dec. 31, 2013	Feb. 27, 2014	Sep. 30, 2014	May 16, 2013	Oct. 22, 2012	Aug. 06, 2012	Dec. 31, 2007	Dec. 31, 2012	Jun. 15, 2012	Aug. 28, 2012 patients	Jun. 20, 2014	Jul. 31, 2013
Commitments and Contingencies (Textual)
Research recorded fees	$ 12,267,313us-gaap_ResearchAndDevelopmentExpense	$ 3,109,331us-gaap_ResearchAndDevelopmentExpense
Total project estimated to cost												800,000us-gaap_DevelopmentInProcess
Research and development costs	700,000us-gaap_ResearchAndDevelopmentInProcess
Security deposit	34,733us-gaap_SecurityDeposit
Letter of credit	34,733us-gaap_LineOfCredit
Manufacturing Agreement [Member]
Commitments and Contingencies (Textual)
Project estimated cost for clinical trials of drug Ac-225-HuM195	2,200,000		3,300,000
Non - refundable institutional fee			562,790
Research and development costs	662,239
Einstein [Member]
Commitments and Contingencies (Textual)
Total project estimated to cost				183,391
Research and development costs				92,000
Abbview Biotherapeutics Corp [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
License fee payment	3,000,000
Milestones payments	7,750,000
Description of royalty payment	Company shall pay to AbbVie Biotherapeutics Corp on a country-by-country basis a royalty of 12% of net sales of all licensed products until the later of: (1) 12.5 years after the first commercial sale, or (2) when the patents expire.
Royalty of net sales percentage	12.00%
First commercial sale period	12 years 6 months
Abbview Biotherapeutics Corp [Member] \| After First Net Sales [Member]
Commitments and Contingencies (Textual)
Milestones payments	1,500,000
Abbview Biotherapeutics Corp [Member] \| Phase I Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
Milestones payments	750,000
Abbott Biotherapeutics Corp [Member] \| After First Net Sales [Member] \| Product Development and Patent License Agreement [Member]
Commitments and Contingencies (Textual)
Net sales in milestones payment	10,000,000
Abbott Biotherapeutics Corp [Member] \| Phase I Clinical Trial of a licensed product [Member]
Commitments and Contingencies (Textual)
Milestones payments	750,000
Aptiv Solutions [Member]
Commitments and Contingencies (Textual)
Project estimated cost for clinical trials of drug Ac-225-HuM195					2,200,000	2,200,000	2,200,000
Down payment of project estimated cost percentage	12.50%
Down payment for project	1,900,000							239,000	239,000
Total project estimated to cost	2,700,000
Research and development costs	388,000	270,000
Fred Hutchinson Cancer Research Center [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Milestones payments										1,000,000
Description of royalty payment	Royalty payments of 2% of net sales will be due to FHCRC.
Royalty of net sales percentage										2.00%
Fund for Fred Hutchinson Cancer Research Center lab ( Per year for the first two years )										150,000
Fund for Fred Hutchinson Cancer Research Center lab ( thereafter )										250,000
Research recorded fees	222,000	75,000
Fred Hutchinson Cancer Research Center [Member] \| Maximum [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration										23,500,000
Fred Hutchinson Cancer Research Center [Member] \| Minimum [Member] \| license and sponsored research agreement [Member]
Commitments and Contingencies (Textual)
Clinical trial cost for approval of food and drug administration										13,200,000
University of Texas M.D. Anderson Cancer Center [Member] \| Clinical Trial Agreement [Member]
Commitments and Contingencies (Textual)
Number of Patients											24
Amount paid to each patient after Completing clinical trial											500,000		34,383
Start-up fee for clinical trial											33,946
Start-up due cost paid date											Dec. 31, 2013
Non - refundable institutional fee											14,500
Research recorded fees	102,000
Johns Hopkins University [Member] \| Clinical Trial Agreement [Member]
Commitments and Contingencies (Textual)
Amount paid to each patient after Completing clinical trial